The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count
- 1 March 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (5) , F23-F28
- https://doi.org/10.1097/00002030-199805000-00003
Abstract
To determine the value of plasma HIV-1 RNA and CD4 cell count as predictors of the clinical benefit of antiretroviral treatment. The CAESAR (Canada, Australia, Europe, South Africa) trial randomized 1840 patients (inclusion CD4 cell count, 25–250 × 106/l) to add either placebo, lamivudine (3TC) or 3TC plus loviride in a double-blinded fashion to baseline treatments (zidovudine, zidovudine–didanosine or zidovudine–zalcitabine) for 1 year. This analysis included 487 patients with data on CD4 cell count and HIV-1 RNA after 12–20 weeks of treatment and subsequent follow-up for clinical progression. The correlation between 12–20-week change in CD4 cell count, HIV-1 RNA and progression to AIDS or death in the placebo group was used to predict the clinical benefit of the 3TC-containing arms of the trial, given their effects on CD4 cell count and HIV-1 RNA. After 12–20 weeks of treatment, HIV-1 RNA fell by 0.37 log10 copies/ml in the 3TC arms versus a rise of 0.05 log10 copies/ml in the placebo arm. The 12–20-week CD4 cell count rose by 35 × 106/l in the 3TC arm versus a fall of 8 × 106/l in the placebo arm. After 12–20 weeks of treatment, a reduction in HIV-1 RNA of 1 log10 at 12–20 weeks predicted a 49% reduction in progression [hazard ratio (HR), 0.51; 95% confidence interval (CI), 0.30–0.87] and a rise in CD4 cell count of 50 × 106/l predicted a 51% reduction in progression (HR, 0.49; 95% CI, 0.33–0.73). Using the model from the placebo arm, the rises in CD4 cell count and reductions in HIV-1 RNA during 3TC treatment predicted a 59% reduction in progression to AIDS or death. The observed clinical benefit was a 57% reduction in progression for the 3TC arms versus placebo (HR, 0.43; 95% CI, 0.26–0.71). Rises in CD4 cell count and reductions in HIV-1 RNA were reliable in predicting the clinical benefit of 3TC in the CAESAR trial.Keywords
This publication has 10 references indexed in Scilit:
- Meta-analysis for the evaluation of potential surrogate markersStatistics in Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection.The Journal of Infectious Diseases, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panelPublished by American Medical Association (AMA) ,1997
- Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 InfectionAnnals of Internal Medicine, 1997
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trialThe Lancet, 1997
- Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individualsAIDS, 1997
- Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 InfectionAnnals of Internal Medicine, 1996
- Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDSNew England Journal of Medicine, 1996
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992